Contack us Worldwide locations Sitemap Home
ȸ»ç¼Ò°³ »ç¾÷ºÎ¹® »õ¼Ò½Ä °Ô½ÃÆÇ Investors
»ç¾÷ºÎ¹®
overview
Orthopaedics
endoscopy
woundmanagement
Á¦Ç°¼Ò°³
Chronic Wound Care
Allevyn Standard
Allevyn Adhesive
Allevyn
Acticoat
Replicare Ultra
IntraSite Gel
IntraSite Conformable
Aliginates
OpSite Flexifix
OpSite Flexigrid
Acute Wound Care
OpSite Post-Op
OpSite Incise Drapes
OpSite IV 3000
Scar Therapy
Cica-Care
Education
FAQ
»õ¼Ò½Ä
Medical Term Glossary
Wound Management

OpSite* Flexifix* (¿É»çÀÌÆ® Ç÷º½ÃÇȽº)

Á¦Ç° Ư¼º

  • Åõ¸íÇÑ Çʸ§
  • À¯¿¬¼º
  • µ¶Æ¯ÇÑ ·Ñ ÇüÅÂ

Á¦Ç°ÀÇ ÀåÁ¡

Opsite film (¿É»çÀÌÆ® Çʸ§)
Çʸ§Àº ¹æ¼ö ¹ÚÅ׸®¾Æ¸¦ Â÷´ÜÀÌ °¡´ÉÇϸç.³ôÀº ¼öºÐ Áõ¹ß·ÂÀÌ ÇǺΰ¡ ¼û½¬´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
¾ÆÅ©¸± Á¢ÂøÁ¦ ¼ººÐÀº µå·¹½Ì ±³Ã¼½Ã, Àå½Ã°£ »ç¿ë ÈÄ¿¡ ÇǺΠ¼Õ»óÀÇ À§Ç輺À» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù.
±¼°îÁø ºÎÀ§¿¡ Àû¿ëÀÌ À¯¸®ÇÕ´Ï´Ù.
¿É»çÀÌÆ® Ç÷º½ÃÇȽº´Â ±¼°îÁø ½ÅüºÎÀ§³ª Ä«Å×ÅÍ °íÁ¤¿ë µå·¹½ÌÀ¸·Î ½±°Ô Àû¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

µ¶Æ¯ÇÑ ·Ñ ÇüÅÂ
µ¶Æ¯ÇÑ ·Ñ ÇüÅÂÀ̱⠶§¹®¿¡ µå·¹½Ì °íÁ¤À» ¾ÈÀüÇÏ°Ô Çϸç, ¹æ¼ö°¡´ÉÇÒ »Ó ¾Æ´Ï¶ó ºü¸£°Ô Àû¿ëÇÒ ¼ö ÀÖ¾î °æÁ¦ÀûÀÎ ÀÕÁ¡ÀÌ ÀÖ½À´Ï´Ù.

ÀûÀÀÁõ

´ÙÀ½°ú °°Àº ¿ëµµ·Î »ç¿ë ÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • 1Â÷ µå·¹½ÌÀÇ °íÁ¤ (¾Ë·¹ºó ~ ÇÏÀ̵å·Î¼¿·ê¶ó Æú¸®¿ì·¹Åº µå·¹½Ì)
  • Ä«Å×ÅÍÀÇ °íÁ¤
  • ¸»ÃÊ ½Å°æº´Áõ ȯÀÚÀÇ ÅëÁõ °ü¸®
  • leg bag, stoma ÀåÄ¡ ÁÖº¯ÀÇ ÇǺΠº¸È£


Product Availability
Code
Size
Q'ty /Carton
66000040
5cm x 10cm
1°³
66000041
10cm x 10cm
1°³

»ç¿ë¹ý

Step 1:
¿øÇÏ´Â ±æÀ̸¸Å­ ·ÑÀ» Àý´ÜÇÕ´Ï´Ù.

Step 2:
º¸È£Áö Áß°£À» ¹úÀ̸鼭 ±æÀ̸¸Å­ ¹þ°Ü³À´Ï´Ù.
1¹øÀ̶ó°í ÀμâµÈ À̸éÁö¸¦ Á¦°ÅÇÕ´Ï´Ù.

Step 3:
Çʸ§À» ¿øÇÏ´Â ºÎÀ§¿¡ ºÎµå·´°Ô Àû¿ëÇÕ´Ï´Ù.

Step 4:
³ì»öÀÇ Áß°£Áö¸¦ Á¦°ÅÇÕ´Ï´Ù.

Step 5:
Çʸ§À» Á¦°ÅÇÒ ¶§´Â ÇÇºÎ¿Í ¼öÆò¹æÇâÀ¸·Î °¡º±°Ô ´ÃÀ̸鼭 Á¦°ÅÇÕ´Ï´Ù.

ÀÓ»óÀÚ·á

Paper title:
Application of OpSite* Flexigrid*: film: a new and effective treatment of painful diabetic neuropathy.

Author:
A V M Foster, C Eaton, D O McConville, M E Edmonds

Reference:
Diabetic Medicine (1994) 11: 768-772

Study abstract:
The aim of the study was to assess the effect of application of OpSite* dressings on the pain and quality of life in 33 patients with chronic diabetic neuropathy. The effect of OpSite was compared with no treatment. After a run-in period of 2 weeks, OpSite was applied to one of the painful legs for 4 weeks. This was followed by another period of 4 weeks when OpSite was switched to the opposite leg. Pain was assessed by visual analogue scale and the primary analysis variable was within patient difference in pain between OpSite leg and no treatment leg as week 4 corrected for baseline. Secondary variables were paracetamol pill ingestion and the quality of life dimensions, sleep, mobility, contact, discomfort, appetite and mood. Changes in these variables from baseline to weeks 4 and 8 were analysed. There was a significantly greater reduction in pain in the OpSite treated limbs than the control limbs (p < 0.001). By week 4 paracetamol intake also declined significantly (p = 0.034) and patients experienced a significant improvement in contact discomfort, sleep, mood, appetite and mobility (p < 0.002 for all 5 variables). OpSite appeared to alleviate the pain associated with diabetic painful neuropathy and thus improved patient’s quality of life.